Effect of selumetinib on the growth of anastrozole-resistant tumors
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://link.springer.com/content/pdf/10.1007/s10549-013-2474-5.pdf
Reference46 articles.
1. Goss PE, Muss HB, Ingle JN, Whelan TJ, Wu M (2008) Extended adjuvant endocrine therapy in breast cancer: current status and future directions. Clin breast cancer 8:411–417. doi: 10.3816/CBC.2008.n.049
2. Swain SM (2005) Aromatase inhibitors–a triumph of translational oncology. N Engl J Med 353:2807–2809
3. Baum M (2002) The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment. Eur J Cancer 38:1984–1986
4. Buzdar A (2003) Anastrozole as adjuvant therapy for early-stage breast cancer: implications of the ATAC trial. Clin breast cancer 4(Suppl 1):S42–S48
5. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262–1271
Cited by 12 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Selumetinib: a selective MEK1 inhibitor for solid tumor treatment;Clinical and Experimental Medicine;2022-02-16
2. Efficacy of a novel orally active SERD AZD9496 against hormone dependent post-menopausal breast cancer depends on inhibition of cellular aromatase activity;The Journal of Steroid Biochemistry and Molecular Biology;2020-09
3. Acquired resistance to aromatase inhibitors: where we stand!;Endocrine-Related Cancer;2018-05
4. Revisiting the IGF-1R as a breast cancer target;npj Precision Oncology;2017-05-01
5. Treatment with aromatase inhibitors stimulates the expression of epidermal growth factor receptor-1 and neuregulin 1 in ER positive/HER-2/neu non-amplified primary breast cancers;The Journal of Steroid Biochemistry and Molecular Biology;2017-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3